Neuberger Berman Group LLC Beam Therapeutics Inc. Transaction History

Neuberger Berman Group LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$29.32 - $35.99 $244,851 - $300,552	8,351 Added 27.13%	39,132 $1.25 Million
Q1 2023 May 12, 2023	BUY	$30.15 - $48.79 $32,833 - $53,132	1,089 Added 3.67%	30,781 $942,000
Q4 2022 Feb 13, 2023	BUY	$36.73 - $51.6 $269,708 - $378,898	7,343 Added 32.86%	29,692 $1.16 Million
Q3 2022 Nov 15, 2022	SELL	$39.79 - $70.31 $2,864 - $5,062	-72 Reduced 0.32%	22,349 $1.07 Million
Q2 2022 Aug 15, 2022	SELL	$29.86 - $62.36 $6,210 - $12,970	-208 Reduced 0.92%	22,421 $868,000
Q1 2022 May 13, 2022	SELL	$53.73 - $82.16 $209,547 - $320,424	-3,900 Reduced 14.7%	22,629 $1.26 Million
Q4 2021 Feb 11, 2022	SELL	$68.02 - $99.06 $272 - $396	-4 Reduced 0.02%	26,529 $2.07 Million
Q3 2021 Nov 12, 2021	BUY	$84.37 - $133.6 $61,168 - $96,860	725 Added 2.81%	26,533 $2.26 Million
Q2 2021 Aug 13, 2021	BUY	$64.12 - $128.71 $1.65 Million - $3.32 Million	25,808 New	25,808 $3.32 Million

236

75.2M

438K

232K

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.78B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

Get notified when there are updates to the investment portfolio of Neuberger Berman Group LLC, based on Form 13F filings with the SEC.

Stay updated on Neuberger Berman Group LLC with notifications on news.